Endpoints NewsOriginal article
AstraZeneca’s pipeline struggles continue as it reports disappointing data in cancer, rare disease
Data ReadoutnegativeUltomirisNegative
AI Analysis
Summary
AstraZeneca reported disappointing results from two late-stage trials: an antibody-drug conjugate in stomach cancer and Ultomiris in a rare disease, signaling continued pipeline challenges for the company.
Clinical Trial Data
Phase
late-stage
Primary Endpoint
Not Met
Outcome Details
Two late-stage trials yielded subpar results - an antibody-drug conjugate in stomach cancer and Ultomiris in a rare disease
Importance:7/10
Sentiment:
-0.80
clinical_setbackpipeline_challengeslate-stage_trialsoncologyrare_disease
Related Companies
Read the original article
Published by Endpoints News on July 27, 2026 11:03 AM